Skip Navigation LinksHome > May 2013 - Volume 113 - Issue 5 > New Antidiabetic Drug in Three Preparations
AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000430229.99197.75
Drug Watch

New Antidiabetic Drug in Three Preparations

Aschenbrenner, Diane S. MS, RN

Collapse Box


* Alogliptin (Nesina) is the newest dipeptidyl peptidase-4 inhibitor approved for the treatment of type 2 diabetes. It's also available as part of two combination therapies—called Kazano when combined with metformin and Oseni when combined with pioglitazone.

* The most common adverse effects are upper respiratory infections, nasopharyngitis, and headache. Alogliptin may also cause acute pancreatitis, severe liver disease, and severe allergic reactions. Hypoglycemia is possible if the drug is administered with a sulfonylurea or with insulin.

© 2013 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics